When BRAF and NRAS mutation were analysed separately, patients with BRAF mutant tumours compared to patients with BRAF/NRAS wild-type tumours had increased risk of developing disease recurrence following a negative SLNB (aHR 2.07, 95% CI 1.05–4.09, p = 0.04). Here, BRAF is linked to neoplasm.